Novocure Limited (NASDAQ: NVCR) recently announced that its innovative product Optune Lua® has received reimbursement approval from Japanese regulators for the treatment of non-small cell lung cancer (NSCLC).

Novocure Limited (NASDAQ: NVCR) recently announced that its innovative product Optune Lua® has received reimbursement approval from Japanese regulators for the treatment of non-small cell lung cancer (NSCLC).

老虎证券2026/03/02 12:41

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This important milestone means that eligible Japanese non-small cell lung cancer patients will be able to receive insurance coverage for this therapy, thereby reducing the financial burden of treatment. Optune Lua® is a non-invasive cancer therapy that utilizes Tumor Treating Fields (TTFields) technology. The approval for reimbursement is expected to enhance the accessibility of this therapy in Japan, providing a new treatment option for more patients.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Microsoft has announced a major upgrade to Copilot: Word, Excel and PowerPoint will be directly integrated into this AI assistant. Additionally, new programming tool Code and a continuously running AI agent called Autopilot have been introduced, aiming to transform Copilot from a single AI assistant into a one-stop solution for office work, programming, and task execution.

华尔街见闻•2026/09/26 00:41